N-(4-phenylbutyl)cyanoacetamide | 133550-40-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-phenylbutyl)cyanoacetamide
• 英文别名: 2-cyano-N-(4-phenylbutyl)acetamide
• CAS: 133550-40-0
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.283
• InChiKey: MNMZOWPSRMYOPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-phenylbutyl)cyanoacetamide 在 sodium azide 、 三乙胺盐酸盐 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以86%的产率得到N-(4-phenylbutyl)-2-(1H-tetrazol-5-yl)acetamide
  参考文献：
  名称：

  易于合成的两个位置异构的四唑图书馆

  摘要：

  摘要 为了测试基于片段的药物发现中的异构四唑的结合假设，描述了位置异构体1 H-四唑和5 H-四唑的文库的快速有效合成。 为了测试基于片段的药物发现中的异构四唑的结合假设，描述了位置异构体1 H-四唑和5 H-四唑的文库的快速有效合成。

  DOI：

  10.1055/s-0035-1562435
• 作为产物：
  描述：

  苯基-4-丁胺 、 氰乙酸甲酯 反应 16.0h， 以51%的产率得到N-(4-phenylbutyl)cyanoacetamide
  参考文献：
  名称：

  Tyrphostins. II. Heterocyclic and .alpha.-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases

  摘要：

  We have previously described a novel series of low molecular weight protein tyrosine kinase inhibitors which we named tyrphostins. The characteristic active pharmacophore of these compounds was the hydroxy-cis-benzylidenemalononitrile moiety. In this article we describe three novel groups of tyrphostins: (i) one group has the phenolic moiety of the cis-benzylidenemalononitrile replaced either with other substituted benzenes or with heteroaromatic rings, (ii) another is a series of conformationally constrained derivatives of hydroxy-cis-benzylidenemalononitriles in which the malononitrile moiety is fixed relative to the aromatic ring, and (iii) two groups of compounds in which the position trans to the benzenemalononitrile has been substituted by ketones and amides. Among the novel tyrphostins examined we found inhibitors which discriminate between the highly homologous EGF receptor kinase (HER1) and ErbB2/neu kinase (HER2). These findings may lead to selective tyrosine kinase blockers for the treatment of diseases in which ErbB2/neu is involved.

  DOI：

  10.1021/jm00110a022

文献信息

• [EN] DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME<br/>[FR] INHIBITEURS DE DÉUBIQUITINASE ET MÉTHODES D'UTILISATION DE CEUX-CI
  申请人：UNIV MICHIGAN

  公开号：WO2015054555A1

  公开（公告）日：2015-04-16

  Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I)

  本文披露了通过与式（I）化合物接触来抑制去泛素酶（DUB）的方法。
• [EN] SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF<br/>[FR] LIGANDS DU RECEPTEUR N-METHYL-D-ASPARTATE SELECTIFS DE SOUS-TYPE
  申请人：STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON

  公开号：WO1997023202A1

  公开（公告）日：1997-07-03

  (EN) The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's diseae, Parkinson's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence and inducing anesthesia, as well as for enhancing cognition, treating or preventing opiate tolerance, treating or preventing aminoglycoside antibiotic induced hearing loss, and treating opiate withdrawal.(FR) Cette invention a trait à des ligands du récepteur N-méthyl-D-aspartate (NMDA) sélectifs de sous-type et à leur utilisation dans le traitement ou la prévention de la dépopulation neuronale associée à un ictus, une ischémie, une lésion du système nerveux central, une hypoglycémie et à un acte chirurgical, ainsi que dans le traitement de maladies neurodégénérescentes, au nombre desquelles la maladie d'Alzheimer, la sclérose latérale amyotrophique, les maladies d'Huntington et de Parkinson ainsi que le syndrome de Down. Ces ligands sont également utilisés dans le traitement et la prévention des conséquences préjudiciables d'une stimulation excessive d'acides aminés excitateurs, le traitement de l'anxiété, de psychoses, de convulsions, de douleurs chroniques, du glaucome, de la rétinite à cytomégalovirus, de l'incontinence urinaire et pour le déclenchement de l'anesthésie ainsi que comme tonique cérébro-actif. Ces ligands sont, en outre, utilisés dans le traitement et la prévention de l'accoutumance opiacée et le traitement du sevrage des dépendances aux opiacés ainsi que pour le traitement et la prévention du déficit auditif provoqué par des aminoglycosides.

  本发明涉及亚型选择性NMDA受体配体及其在治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化症、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、癫痫、慢性疼痛、青光眼、CMV视网膜炎、尿失禁和诱导麻醉，以及增强认知能力，治疗或预防阿片类药物耐受性，治疗或预防氨基糖苷类抗生素引起的听力损失，和治疗阿片类药物戒断症状的用途。
• Aminoisoxazole derivatives active as kinase inhibitors
  申请人：Cavicchioli Marcello

  公开号：US20050059657A1

  公开（公告）日：2005-03-17

  Compounds (I) which are aminoisoxazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明涉及氨基异噁唑衍生物(I)或其药学上可接受的盐，以及包含它们的药物组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• Structure−Activity Relationship of <i>N</i>-(Phenylalkyl)cinnamides as Novel NR2B Subtype-Selective NMDA Receptor Antagonists
  作者：Amir P. Tamiz、Sui Xiong Cai、Zhang-Lin Zhou、Po-Wai Yuen、Robert M. Schelkun、Edward R. Whittemore、Eckard Weber、Richard M. Woodward、John F. W. Keana

  DOI：10.1021/jm990199u

  日期：1999.8.1

  A novel series of N-(phenylalkyl)cinnamides related to N-(4-phenylbutyl)-3,4-dihydroxy-beta-cyanocinnamide (6, an EGFR-K inhibitor with high antiproliferative activity) was synthesized and tested for antagonism at N-methyl-D-aspartate (NMDA) receptor subtypes. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The N-(phenylalkyl)cinnamides are selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, N-(4-phenylbutyl)-4-hydroxycinnamide (16) has an IC50 value of 77 nM and >1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. Potency at alpha(1) adrenergic receptors is low for the four cinnamides tested. Inhibition of NR1A/2B receptors does not correlate with EGFR and ErbB2/neu tyrosine kinase inhibitor activity. The N-(phenylalkyl)cinnamide series we describe provides a novel and structurally diverse framework for designing new NR2B-selective NMDA antagonists as potential CNS therapeutics.
• Cyanoacetamides (IV): Versatile One-Pot Route to 2-Quinoline-3-carboxamides
  作者：Kan Wang、Eberhardt Herdtweck、Alexander Dömling

  DOI：10.1021/co3000133

  日期：2012.5.14

  Cyanoacetic acid derivatives are the starting materials for a plethora of multicomponent reaction (MCR) scaffolds. Herein, we describe scope of a valuable general protocol for the synthesis of arrays of 2-aminoquinoline-3-carboxamides from cyanoacetamides and 2-aminobenzaldehydes or heterocyclic derivatives via a Friedlander reaction variation. In many cases, the reactions involve a very convenient work up by simple precipitation and filtration. More than 40 new products are described. We foresee our protocol and the resulting derivatives becoming very valuable to greatly expanding the scaffold space of cyanoacetamide derivatives.